[go: up one dir, main page]

ES2117272T3 - Composiciones farmaceuticas orales que comprenden una proteina o peptido, un anticuerpo y esferas polimericas. - Google Patents

Composiciones farmaceuticas orales que comprenden una proteina o peptido, un anticuerpo y esferas polimericas.

Info

Publication number
ES2117272T3
ES2117272T3 ES94916352T ES94916352T ES2117272T3 ES 2117272 T3 ES2117272 T3 ES 2117272T3 ES 94916352 T ES94916352 T ES 94916352T ES 94916352 T ES94916352 T ES 94916352T ES 2117272 T3 ES2117272 T3 ES 2117272T3
Authority
ES
Spain
Prior art keywords
peptide
protein
antibody
pharmaceutical compositions
compositions including
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94916352T
Other languages
English (en)
Inventor
Michael Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Babraham Institute
Original Assignee
Babraham Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Babraham Institute filed Critical Babraham Institute
Application granted granted Critical
Publication of ES2117272T3 publication Critical patent/ES2117272T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6943—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a pill, a tablet, a lozenge or a capsule

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

LAS COMPOSICIONES FARMACEUTICAS PARA ADMINISTRACION ORAL COMPRENDEN UNA PROTEINA O PEPTIDO,UN ANTICUERPO QUE ESPECIFICO PARA LA PROTEINA Y UNA PLURALIDAD DE PERLAS POLIMERICAS. LAS COMPOSICIONES PERMITEN QUE PROTEINAS Y PEPTIDOS SEAN APROPIADAS PARA SU ADMINISTRACION ORAL.
ES94916352T 1993-06-03 1994-06-02 Composiciones farmaceuticas orales que comprenden una proteina o peptido, un anticuerpo y esferas polimericas. Expired - Lifetime ES2117272T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB939311454A GB9311454D0 (en) 1993-06-03 1993-06-03 Pharmaceutical compositions

Publications (1)

Publication Number Publication Date
ES2117272T3 true ES2117272T3 (es) 1998-08-01

Family

ID=10736565

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94916352T Expired - Lifetime ES2117272T3 (es) 1993-06-03 1994-06-02 Composiciones farmaceuticas orales que comprenden una proteina o peptido, un anticuerpo y esferas polimericas.

Country Status (9)

Country Link
EP (1) EP0707473B1 (es)
AT (1) ATE164311T1 (es)
AU (1) AU6804394A (es)
DE (1) DE69409237T2 (es)
DK (1) DK0707473T3 (es)
ES (1) ES2117272T3 (es)
GB (1) GB9311454D0 (es)
WO (1) WO1994028879A1 (es)
ZA (1) ZA943920B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1275380A1 (en) * 1997-01-30 2003-01-15 Chiron Corporation Use of microparticles with adsorbed antigen to stimulate immune responses
US6884435B1 (en) 1997-01-30 2005-04-26 Chiron Corporation Microparticles with adsorbent surfaces, methods of making same, and uses thereof
DK0991403T3 (da) * 1997-01-30 2003-07-28 Chiron Corp Anvendelse af mikropartikler med adsorberet antigen til stimulering af immunresponser
IT1291559B1 (it) * 1997-04-14 1999-01-11 Univ Degli Studi Milano Uso di microparticelle su cui sono stati adsorbiti una proteina ed un anticorpo per preparare una composizione farmaceutica somministrabile
CN1535140A (zh) 2000-09-28 2004-10-06 ϣ 微粒体组合物及其生产方法
EP1900753B1 (en) 2002-11-08 2017-08-09 Ablynx N.V. Method of administering therapeutic polypeptides, and polypeptides therefor
AU2003283137B8 (en) 2002-11-08 2010-07-29 Ablynx N.V. Camelidae antibodies against immunoglobulin E and use thereof for the treatment of allergic disorders
KR20080113286A (ko) 2003-01-10 2008-12-29 아블린쓰 엔.브이. 폰 빌레브란트 인자(ｖＷＦ) 또는 콜라겐에 대한 낙타과로부터의 재조합 ＶＨＨ 단일 도메인 항체
DE602004022286D1 (de) 2003-06-02 2009-09-10 Novartis Vaccines & Diagnostic Immunogene zusammensetzungen auf basis von biologisch abbaubaren mikroteilchen enthaltend ein diphtherie- und ein tetanustoxoid
EP1687338B1 (en) 2003-11-07 2010-10-20 Ablynx N.V. Camelidae single domain antibodies vhh directed against epidermal growth factor receptor and uses thereof
RU2464276C2 (ru) 2005-05-18 2012-10-20 Аблинкс Н.В. Улучшенные нанотела против фактора некроза опухоли-альфа
CA2608873C (en) 2005-05-20 2017-04-25 Ablynx Nv Single domain vhh antibodies against von willebrand factor

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2595826B1 (fr) * 1986-03-13 1990-09-07 Lurhuma Zirimwabagabo Produit d'immuno-essai, son procede de preparation, son utilisation, complexe immunogene le comportant et utilisation de ce complexe
JP3296817B2 (ja) * 1991-04-02 2002-07-02 バイオテック・オーストラリア・ピーティーワイ・リミテッド 微粒子に適した経口配布系

Also Published As

Publication number Publication date
ATE164311T1 (de) 1998-04-15
AU6804394A (en) 1995-01-03
EP0707473A1 (en) 1996-04-24
EP0707473B1 (en) 1998-03-25
DE69409237T2 (de) 1998-10-29
ZA943920B (en) 1995-12-04
DK0707473T3 (da) 1999-01-04
DE69409237D1 (de) 1998-04-30
WO1994028879A1 (en) 1994-12-22
GB9311454D0 (en) 1993-07-21

Similar Documents

Publication Publication Date Title
BR9607317A (pt) Peptídios e composição farmacêutica
BR9607318A (pt) Peptidos e composição farmacêutica
FI954978L (fi) Modifioidut proteiini- ja peptidilääkeaineet
DK0776885T3 (da) Biaromatiske forbindelser indeholdende en adamantylgruppe i positionen ortho, farmaceutiske og kosmetiske præparater, der i
EA199800946A1 (ru) Концентрированный препарат антител
NL194828B (nl) Somatostatinepeptiden, alsmede dergelijke somatostatinepeptiden bevattende farmaceutische preparaten.
NO306342B1 (no) Syntetiske eksitatoriske aminosyrer, farmasöytisk formulering inneholdende slike aminosyrer samt mellomprodukt
DE122005000024I1 (de) Darifenacin enthaltende Pharmazeutische Zubereitungen.
BR9611367A (pt) Formulação farmacêutic liofilizada estável
FI942005L (fi) Peptidianalogeja irreversiibeleinä interleukiini-1beta-proteaasi-inhibiittoreina
FI955907L (fi) Laite farmaseuttisten aineiden antamiseksi
IS4345A (is) Setin N-(indól-2-karbónýl)-b-alaninamíð, notkun þeirra og lyfjaefnablöndur
ES2117272T3 (es) Composiciones farmaceuticas orales que comprenden una proteina o peptido, un anticuerpo y esferas polimericas.
SE9403526D0 (sv) New Peptides
ES2118939T3 (es) Peptido para el diagnostico e inmunizacion contra la infeccion con t.cruzi.
DE69520475D1 (de) Pharmaceutische Zusammensetzung von biologisch aktiven Peptiden oder Proteinen
NO982874D0 (no) Farmas°ytiske preparater med vitamin D-analoger
FI954986L (fi) Uudet, suun kautta annettavat, syklosporiinia sisältävät farmaseuttiset valmisteet
DE69617396D1 (de) T-Zellen beeinflussende Peptide
DE69626522D1 (de) Peptide mit pronociceptiveigenschaften
AR004377A1 (es) UNA PROTEINA BIOLOGICAMENTE ACTIVA INHIBIDORA DE KAPA B (NF k B), UNA SECUENCIA DE ACIDO NUCLEICO, UN VECTOR DE EXPRESION, UN ANTICUERPO CONTRADICHA PROTEINA, UN PROCESO PARA SU PREPARACION, UNA COMPOSICION FARMACEUTICA Y EL USO DE DICHA PROTEINA PARA LA PREPARACION DE COMPOSICIONES FARMACEUTICAS.
ATE207935T1 (de) Antikörper gegen ein, einen histidin-anteil aufweisendes fusionspolypeptid
DK0614910T3 (da) Renset form af streptograminer, dens fremstilling og farmaceutiske præparater indeholdende denne form
DE69427363D1 (de) Plättchenaggregationsinhibierende peptide
PT833919E (pt) Toxina botulinica do tipo f e sua utilizacao

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 707473

Country of ref document: ES